Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -38.2% | 57.3% | -35.6% | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 20.3% | 61.3% | 42.6% | 61.1% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -109.3% | -19% | -97.3% | -28.9% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -138.2% | -32.6% | -113.6% | -46.6% |
| EPS Diluted | -0.006 | -0.002 | -0.007 | -0.006 |
| % Growth | -165.2% | 64.6% | -12.1% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |